128 related articles for article (PubMed ID: 8890706)
1. Interleukin-6 receptor expression in the peripheral B cells of patients with multicentric Castleman's disease.
Ishiyama T; Koike M; Nakamura S; Kakimoto T; Akimoto Y; Tsuruoka N
Ann Hematol; 1996 Oct; 73(4):179-82. PubMed ID: 8890706
[TBL] [Abstract][Full Text] [Related]
2. The presence of CD28-negative T cells in a patient with multicentric Castleman's disease.
Ishiyama T; Koike M; Kakimoto T; Akimoto Y; Tsuruoka N
Ann Hematol; 1996 Oct; 73(4):199-200. PubMed ID: 8890710
[TBL] [Abstract][Full Text] [Related]
3. Apoptosis of T cells in multicentric Castleman's disease.
Ishiyama T; Koike M; Fukuchi K; Tomoyasu S; Yoshida M; Wakabayashi Y; Tsuruoka N
Clin Immunol Immunopathol; 1996 Jun; 79(3):271-7. PubMed ID: 8635286
[TBL] [Abstract][Full Text] [Related]
4. Immunodeficiency and IL-6 production by peripheral blood monocytes in multicentric Castleman's disease.
Ishiyama T; Nakamura S; Akimoto Y; Koike M; Tomoyasu S; Tsuruoka N; Murata Y; Sato T; Wakabayashi Y; Chiba S
Br J Haematol; 1994 Mar; 86(3):483-9. PubMed ID: 8043430
[TBL] [Abstract][Full Text] [Related]
5. A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease.
Koga T; Sumiyoshi R; Kawakami A; Yoshizaki K
Mod Rheumatol; 2019 Mar; 29(2):302-305. PubMed ID: 30285516
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of flow cytometric detection of cell surface interleukin-6 receptors in human myeloma cell lines.
Chen YH; Feng XX; Hagen K
Clin Lab Haematol; 1996 Sep; 18(3):161-9. PubMed ID: 8939386
[TBL] [Abstract][Full Text] [Related]
7. [Clinical application of interleukin-6 receptor antibody].
Nishimoto N; Shima Y; Sasai M; Danno N; Yoshizaki K
Nihon Rinsho Meneki Gakkai Kaishi; 1997 Apr; 20(2):87-94. PubMed ID: 9280606
[TBL] [Abstract][Full Text] [Related]
8. Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice.
Katsume A; Saito H; Yamada Y; Yorozu K; Ueda O; Akamatsu K; Nishimoto N; Kishimoto T; Yoshizaki K; Ohsugi Y
Cytokine; 2002 Dec; 20(6):304-11. PubMed ID: 12633573
[TBL] [Abstract][Full Text] [Related]
9. Autostimulatory effects of IL-6 on excessive B cell differentiation in patients with systemic lupus erythematosus: analysis of IL-6 production and IL-6R expression.
Kitani A; Hara M; Hirose T; Harigai M; Suzuki K; Kawakami M; Kawaguchi Y; Hidaka T; Kawagoe M; Nakamura H
Clin Exp Immunol; 1992 Apr; 88(1):75-83. PubMed ID: 1563109
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics of a concurrent condition of IgG4-RD and Castleman's disease.
Zhang X; Zhang P; Peng L; Fei Y; Zhang W; Feng R; Zhang W
Clin Rheumatol; 2018 Dec; 37(12):3387-3395. PubMed ID: 29948354
[TBL] [Abstract][Full Text] [Related]
11. Comparison of IgG4-Related Lymphadenopathy and Multicentric Castleman's Disease: a Retrospective Study.
Sun C; Xu G; Lin J
Clin Lab; 2018 Oct; 64(10):1671-1678. PubMed ID: 30336525
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation.
Kotake S; Sato K; Kim KJ; Takahashi N; Udagawa N; Nakamura I; Yamaguchi A; Kishimoto T; Suda T; Kashiwazaki S
J Bone Miner Res; 1996 Jan; 11(1):88-95. PubMed ID: 8770701
[TBL] [Abstract][Full Text] [Related]
13. Differential interleukin-6 (IL-6) responses of three established myeloma cell lines in the presence of soluble human IL-6 receptors.
Diamant M; Hansen MB; Rieneck K; Svenson M; Yasukawa K; Bendtzen K
Leuk Res; 1996 Apr; 20(4):291-301. PubMed ID: 8642840
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of the IL-6 gene prevents development of multicentric Castleman's disease in C/EBP beta-deficient mice.
Screpanti I; Musiani P; Bellavia D; Cappelletti M; Aiello FB; Maroder M; Frati L; Modesti A; Gulino A; Poli V
J Exp Med; 1996 Oct; 184(4):1561-6. PubMed ID: 8879230
[TBL] [Abstract][Full Text] [Related]
15. Loss of interleukin-21 leads to atrophic germinal centers in multicentric Castleman's disease.
Yajima H; Yamamoto M; Shimizu Y; Sakurai N; Suzuki C; Naishiro Y; Imai K; Shinomura Y; Takahashi H
Ann Hematol; 2016 Jan; 95(1):35-40. PubMed ID: 26377996
[TBL] [Abstract][Full Text] [Related]
16. The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's disease.
Sun Y; Wang D; Salvadore G; Hsu B; Curran M; Casper C; Vermeulen J; Kent JM; Singh J; Drevets WC; Wittenberg GM; Chen G
Brain Behav Immun; 2017 Nov; 66():156-164. PubMed ID: 28676350
[TBL] [Abstract][Full Text] [Related]
17. Absence of IL-6 receptor expression in fresh childhood Burkitt's lymphoma cells and induction of IL-6 receptors by Epstein-Barr virus in vitro.
Tomeczkowski J; zur Stadt U; Reiter A; Welte K; Sykora KW
Br J Haematol; 1997 May; 97(2):400-8. PubMed ID: 9163607
[TBL] [Abstract][Full Text] [Related]
18. Immunologic study of the hyaline-vascular type of Castleman's disease. A case study.
Kimura H; Watanabe Y; Ohashi N; Kobayashi M; Asai M; Mizukoshi K
Acta Otolaryngol Suppl; 1993; 504():146-50. PubMed ID: 8470523
[TBL] [Abstract][Full Text] [Related]
19. Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease.
Kawabata H; Tomosugi N; Kanda J; Tanaka Y; Yoshizaki K; Uchiyama T
Haematologica; 2007 Jun; 92(6):857-8. PubMed ID: 17550864
[TBL] [Abstract][Full Text] [Related]
20. Practical Management of Castleman's Disease.
Alzahrani MF; Radwi M; Leitch HA
Acta Haematol; 2016; 136(1):16-22. PubMed ID: 27160307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
